Healx

Healx is a clinical-stage biotech applying AI to drug discovery and repurposing for rare diseases.

Its platform analyses drug and disease data at scale to identify novel treatment relationships, enabling multiple discovery programmes to run in parallel.

The lead programme targeting neurofibromatosis type 1 entered Phase 2 trials in 2024; preclinical programmes address rare oncology, polycystic kidney disease and neurodevelopmental conditions including Angelman syndrome.

Healx partners with patient advocacy groups, academic institutions and biopharma companies.